U.S. flag

An official website of the United States government

PMC Full-Text Search Results

Items: 2

1.
Figure 2

Figure 2. From: Efficacy and safety of tiotropium Respimat® SMI in COPD in two 1-year randomized studies.

Kaplan–Meier plot illustrating probability of remaining exacerbation-free over the 48-week treatment period (N = 1990) (P < 0.0001 for tiotropium 5 μg–placebo and tiotropium 10 μg–placebo for mean time [lower quartile] to first exacerbation).
Abbreviations: COPD, chronic obstructive pulmonary disease; SMI, Soft Mist™ Inhaler.

Eric Bateman, et al. Int J Chron Obstruct Pulmon Dis. 2010;5:197-208.
2.
Figure 1

Figure 1. From: Efficacy and safety of tiotropium Respimat® SMI in COPD in two 1-year randomized studies.

The adjusted mean (SEM) trough (a) FEV1 (L) response and (b) FVC (L) response during 48 weeks of treatment with tiotropium 5 μg, tiotropium 10 μg, or placebo (n = 1897) (P < 0.0001 for tiotropium 5 μg–placebo and tiotropium 10 μg– placebo for mean improvement in FEV1and FVC).
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; SMI, Soft Mist™ Inhaler.

Eric Bateman, et al. Int J Chron Obstruct Pulmon Dis. 2010;5:197-208.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center